Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $1.4 billion.

  • Genmab A's Total Current Liabilities rose 9180.11% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year increase of 9180.11%. This contributed to the annual value of $1.4 billion for FY2025, which is 9180.11% up from last year.
  • Per Genmab A's latest filing, its Total Current Liabilities stood at $1.4 billion for Q4 2025, which was up 9180.11% from $741.0 million recorded in Q3 2025.
  • Over the past 5 years, Genmab A's Total Current Liabilities peaked at $1.4 billion during Q4 2025, and registered a low of $368.0 million during Q4 2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $741.0 million (2025), whereas its average is $781.8 million.
  • As far as peak fluctuations go, Genmab A's Total Current Liabilities surged by 10217.39% in 2024, and later skyrocketed by 9180.11% in 2025.
  • Over the past 3 years, Genmab A's Total Current Liabilities (Quarter) stood at $368.0 million in 2023, then surged by 102.17% to $744.0 million in 2024, then surged by 91.8% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q4 2025, $741.0 million for Q3 2025, and $629.0 million during Q2 2025.